Airway Clearance Devices Market - By Device Type, By Application, By Age Group, By End Use - Global Forecast, 2025-2034

Airway Clearance Devices Market Size

The global airway clearance devices market was valued at USD 677.9 million in 2024. The market is expected to reach from USD 711.3 million in 2025 to USD 1.1 billion in 2034, growing at a CAGR of 4.6% during the forecast period, according to the latest report published by Global Market Insights Inc. Growing incidence of respiratory disorders, aging population, technological innovations, and heightened awareness of airway clearance therapies are fueling market growth.

The airway clearance devices market provides innovative healthcare solutions to payers, providers, life sciences companies, and healthcare technology companies to improve regulatory compliance, patient outcomes, and operational efficiency. Solutions include oscillatory PEP devices, high-frequency chest wall oscillation vests, mechanical insufflation-exsufflation devices, and digital health solutions that facilitate efficient airway clearance, disease management, and quality of life.
 

Some of the key players in the market include Baxter, Philips, Electromed, Tactile Systems Technology, and Thayer Medical. These companies keep their competitive advantage alive by making their products constantly innovative, having a solid global reach, forming strategic alliances, and making considerable investments in research and development to address growing clinical demands and increase their market base.
 

The market has increased from USD 529.3 million in 2021 and reached USD 648.6 million in 2023. One of the key drivers is the rising prevalence of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, asthma, and bronchiectasis. These conditions are becoming more widespread due to increasing pollution levels, smoking habits, and lifestyle changes, thereby creating a sustained demand for advanced airway clearance solutions. Additionally, the growing elderly population significantly contributes to market growth, as older individuals are more susceptible to respiratory complications that require airway clearance support.
 

Technological advancements in airway clearance devices have further accelerated adoption. Innovations such as oscillatory positive expiratory pressure (OPEP) devices, high-frequency chest wall oscillation (HFCWO) vests, and mechanical insufflation-exsufflation systems are providing patients with safer, more effective, and user-friendly treatment options. The integration of digital health tools, such as remote patient monitoring devices and connected devices, is also transforming patient management by enabling real-time data tracking and personalized therapy adjustments.
 

Awareness campaigns and educational programs led by healthcare providers and organizations are increasing patient and caregiver understanding of the importance of airway clearance therapies. This is improving diagnosis and treatment adherence, thereby supporting higher device utilization rates. Furthermore, growing healthcare expenditure, favorable reimbursement policies, and government initiatives for respiratory disease management are fueling market expansion globally.
 

Airway clearance devices are medical tools designed to assist patients in removing mucus and secretions from the respiratory tract. They include technologies such as oscillatory PEP devices, chest wall oscillation vests, and mechanical insufflation-exsufflation systems, helping improve lung function, reduce infections, and enhance overall respiratory health and quality of life.
 

Airway Clearance Devices Market Trends

One of the major forces behind the growth of the market is the increase in the incidence of respiratory disorders, which continues to have a serious impact on the overall healthcare scenario worldwide.
 

• Increased incidence of chronic respiratory conditions like chronic obstructive pulmonary disease (COPD), cystic fibrosis, bronchiectasis, and asthma has increased the need for effective airway clearance therapies. Macroeconomic changes like fast-paced urbanization, rising industrialization, and higher pollution rates are making air quality poor, which has a direct influence on respiratory conditions and prompts numerous patients to seek treatment.
   
• Moreover, aging populations further contribute to the incidence of disease since older populations are at greater risk for chronic respiratory sequelae. On the microeconomic front, increasing healthcare costs, favorable insurance coverage, and heightened patient willingness to embrace advanced therapies have enhanced the availability of airway clearance devices in both developed and emerging economies.
   
• Furthermore, lifestyle factors such as smoking, sedentary habits, and obesity are compounding disease burdens, reinforcing the need for consistent airway clearance support. Alongside these drivers, technological advancements are reshaping the treatment landscape, with innovations such as oscillatory positive expiratory pressure (OPEP) devices, high-frequency chest wall oscillation (HFCWO) vests, and mechanical insufflation-exsufflation systems offering non-invasive, effective, and user-friendly solutions.
   
• Integration of digital health platforms and remote monitoring capabilities is enhancing patient engagement and enabling real-time therapy adjustments, improving outcomes while reducing hospital dependency.
   

Airway Clearance Devices Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on the device type, the airway clearance devices market is segmented into high frequency chest wall oscillation (HFCWO), flutter mucus clearance device, intrapulmonary percussive ventilation (IPV), mechanical cough assist devices, positive expiratory pressure (PEP), and other device types.
 

The high frequency chest wall oscillation (HFCWO) segment has asserted its dominance in the market by securing a significant market share of 37.5% in 2024, driven by rising prevalence of chronic respiratory diseases and its effectiveness in enhancing mucus clearance for patients with limited mobility. The segment is expected to exceed USD 406.9 million by 2034, growing at a CAGR of 4.8% during the forecast period.
 

On the other hand, the flutter mucus clearance device segment is expected to grow with a CAGR of 5.3%. The growth of this segment can be attributed to the growing patient preference for portable, cost-effective, and user-friendly devices for managing mild to moderate respiratory conditions.
 

• The high frequency chest wall oscillation (HFCWO) category is one of the market drivers, due to its well-documented ability to treat chronic respiratory conditions like cystic fibrosis, bronchiectasis, and COPD. This type of device provides external vibrations to the chest that release mucus and enable its clearance and is particularly useful for patients with low mobility or those who find it difficult to use manual physiotherapy methods.
   
• Additionally, medical professionals are increasingly prescribing HFCWO devices due to the capacity to minimize the risk of infection and hospitalization, thus enhancing quality of life and decreasing total treatment costs.
   
• Technological developments, such as the incorporation of portable and digitally linked HFCWO vests, further promote patient compliance as well as remote monitoring. These additional advantages guarantee the sustained market leadership of HFCWO devices for global airway clearance devices.
   
• The flutter mucus clearance device segment held a revenue of USD 152 million in 2024, with projections indicating a steady expansion at 5.3% CAGR from 2025 to 2034. The flutter mucus clearance device segment is gaining traction due to its affordability, portability, and ease of use, particularly for patients with mild to moderate respiratory conditions. Patient preference for discreet, self-administered therapies is a major driver of this segment, especially in homecare settings.
   
• Additionally, these devices are cost-effective, making them accessible across diverse income groups and healthcare systems. With healthcare shifting toward preventive care and outpatient management, flutter devices offer a convenient solution that complements broader respiratory care strategies.
   
• The intrapulmonary percussive ventilation (IPV) segment held a revenue of USD 105.1 million in 2024, with projections indicating a steady expansion at 4.3% CAGR from 2025 to 2034. The intrapulmonary percussive ventilation (IPV) segment is driven by its advanced capability to deliver high-frequency bursts of air directly into the lungs, mobilizing secretions and improving airway clearance in patients with severe respiratory conditions.
   
• This technique is particularly valuable for individuals with neuromuscular disorders, acute respiratory distress, or conditions resistant to conventional airway clearance methods. Its ability to simultaneously provide ventilation support and mucus mobilization makes it an essential device in critical care and hospital settings.
   

Based on application, the airway clearance devices market is classified into chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis, neuromuscular, and other applications. The chronic obstructive pulmonary disease (COPD) segment dominated the market with a revenue share of 42% in 2024 and is expected to reach USD 439.3 million within the forecast period.
 

• The market leadership of the COPD segment is mainly fueled by the growing global incidence of COPD, which affects millions of people across the globe. High smoking prevalence, air pollution, and occupational exposure are some of the factors that are fueling increased incidence of COPD, leading to a long-term demand for efficient respiratory management solutions.
   
• COPD patients frequently present with chronic mucus retention and airway obstruction, and airway clearance devices become necessary for the enhancement of lung function, the reduction of exacerbations, and the quality of life. Advances in technology, such as oscillatory PEP devices, high-frequency chest wall oscillation vests, and mechanical insufflation-exsufflation systems, have made treatment more effective, non-invasive, and patient-centered, additional factors for increased adoption.
   
• Moreover, macroeconomic influences like rising healthcare expenditures, insurance coverage, and government programs aimed at the management of respiratory diseases are increasing access to these devices.
   
• The bronchiectasis segment held a revenue of USD 194.6 million in 2024, with projections indicating a steady expansion at 5.1% CAGR from 2025 to 2034. The segment is experiencing significant growth due to the rising prevalence of the condition, which is characterized by permanent airway dilation, chronic infections, and excessive mucus accumulation.
   
• Increasing awareness among healthcare providers and patients about the benefits of airway clearance therapy has led to higher adoption rates. Technological innovations such as high-frequency chest wall oscillation vests, oscillatory PEP devices, and mechanical insufflation-exsufflation systems have made it easier for patients to manage symptoms effectively at home, improving compliance and clinical outcomes.
   

Based on age group, the airway clearance devices market is classified into adult, and pediatric. The adult segment dominated the market with a revenue share of 65% in 2024 and is expected to reach USD 704.6 million within the forecast period.
 

• The market is dominated by the adult segment owing to the very high incidence of chronic respiratory illnesses like chronic obstructive pulmonary disease (COPD), asthma, and bronchiectasis in adults. Developed regions have aging populations, and rising industrialization and urban air pollution have led to an explosion of respiratory ailments demanding long-term therapy.
   
• Adults may have complications due to lifestyle issues, such as smoking, inactivity, and obesity, that further increase the demand for effective airway clearance therapies. Advances in technology, like high-frequency chest wall oscillation (HFCWO) vests, oscillatory positive expiratory pressure (OPEP) devices, and mechanical insufflation-exsufflation systems, are non-invasive, convenient treatments that improve compliance and treatment effectiveness.
   
• Further, growing concern for respiratory health, increased access to healthcare, and supportive reimbursement schemes prompt adults to embrace these therapies. Combined, these micro and macroeconomic factors with ongoing product advancement strengthen the strong market position and long-term growth trend of the adult segment.
   
• The pediatric segment held a revenue of USD 237.4 million in 2024, with projections indicating a steady expansion at 4.1% CAGR from 2025 to 2034. The pediatric segment is driven by the rising incidence of congenital and chronic respiratory conditions among children, such as cystic fibrosis, bronchiectasis, and severe asthma. Early intervention is critical in managing these conditions, creating significant demand for specialized airway clearance solutions designed for pediatric use.
   
• Technological innovations have led to the development of smaller, lightweight, and user-friendly devices, including oscillatory PEP systems and mechanical insufflation-exsufflation devices, ensuring safer and more comfortable therapy for young patients. Parents and caregivers are increasingly aware of the importance of regular airway management in preventing long-term lung damage, boosting adoption rates.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the airway clearance devices market is classified into homecare settings, hospital, ambulatory surgical centers, and other end users. The homecare settings segment dominated the market with a revenue share of 43.7% in 2024 and is expected to reach USD 466.9 million within the forecast period.
 

• The two largest segments account for over 79.7% of the total market value. The homecare settings market holds sway because of the growing patient demand for convenient, home-based respiratory therapy. Increased incidence of chronic respiratory conditions, including COPD, cystic fibrosis, and bronchiectasis, has led to a trend toward care in the home in order to enhance patient comfort, compliance, and quality of life.
   
• Technological innovations, such as portable oscillatory PEP machines, high-frequency chest wall oscillation vests, and mechanical insufflation-exsufflation devices, have improved the efficiency and convenience of treatments at home, so patients can treat themselves with limited supervision. Moreover, digital health integration and remote monitoring systems enable clinicians to monitor the progress of treatment and modify therapies in real time, minimizing hospital visits and expenses.
   
• The hospital segment held a revenue of USD 244.2 million in 2024, with projections indicating a steady expansion at 5% CAGR from 2025 to 2034. The hospital segment is driven by the need for specialized respiratory care and advanced therapeutic interventions for severe or acute cases. Hospitals provide access to trained healthcare professionals who can administer complex airway clearance therapies, such as high-frequency chest wall oscillation, mechanical insufflation-exsufflation, and other device-assisted treatments, ensuring clinical efficacy and safety.
   
• Technological advancements, including digital connectivity and integrated monitoring systems, allow real-time tracking of patient progress, improving treatment outcomes and operational efficiency. Macroeconomic factors, such as rising investment in healthcare infrastructure, expanding hospital networks, and increased funding for respiratory care, support the adoption of these devices.
   

Looking for region specific data?

Download Free PDF

North America Airway Clearance Devices Market
 

North America dominated the market with the highest market share of 38.7% in 2024.
 

• The North American healthcare system is favorable to the adoption of new technologies like air-pulse generator systems and oscillatory devices. These technologies are applied more and more in the home environments, fitting with the government's focus on durable medical equipment in encouraging independent living.
   
• The region's emphasis on patient-centered care and technology to enable patient-centered solutions is accelerating the acceptance of airway clearance therapies.
   
• Moreover, North America has a well-established health network of hospitals, rehabilitation facilities, and home care services that are able to provide airway clearance therapy. For instance, some Medicaid policies, like that of MassHealth in Massachusetts, will pay for devices like SmartVest and inCourage HFCWO on strict clinical grounds for patients suffering from bronchiectasis and neuromuscular diseases.
   
• These devices may be applied both in hospitals and at home, which reduces hospitalization for extended periods and maintains patient independence. This stakeholder strategy ensures that North America continues to lead the development of respiratory therapy solutions and readiness.
   

The U.S. airway clearance devices market was valued at USD 195.6 million and USD 215.9 million in 2021 and 2022, respectively. In 2024, the market size grew to USD 237.7 million from USD 231.2 million in 2023.
 

• Increased adoption by clinicians, liberalized reimbursement policies, and further integration into home-based care models have driven this market growth.
   
• The U.S. market is supported by reimbursement coverage from Medicaid and Medicare for devices such as high-frequency chest wall oscillation systems and oscillatory PEP devices with approved uses for cystic fibrosis (CF), bronchiectasis (BR), and neuromuscular disorders (NMDs) that the FDA has streamlined clearance for through Class II.
   
• Additionally, devices on the market, including high-frequency chest compression systems, have increasingly received approval due to the acceptability of patients self-administering chest physiotherapy, allowing independence and possibly cost reduction.
   
• Furthermore, in 2024, the FDA’s CDRH Annual Report highlighted initiatives such as Home as a Health Care Hub, which promoted the integration of medical devices including airway clearance systems into home environments. This initiative supported broader adoption and market growth by enabling patients to manage chronic respiratory conditions outside of clinical settings.
   
• Collectively, initiatives by the FDA and funding for innovation from NIH have further expended the continued development and use of the newest air clearance technologies and continue to build the framework for favorability for sustainable growth of this marketplace. These factors have created a favorable ecosystem for sustained market growth, positioning the U.S. as a global leader in respiratory therapy solutions.
   

Europe Airway Clearance Devices Market
 

Europe market accounted for USD 180 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• The European airway clearance device market is steadily growing due to an increase in respiratory diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and bronchiectasis, which are becoming more prevalent due to aging populations and environmental factors.
   
• The implementation of the EU Medical Device Regulation (MDR) and the EUDAMED system ensures safety, transparency, and traceability for airway clearance technologies across member states. Organizations like the European Cystic Fibrosis Society promote standardized therapy guidelines, supporting clinical adoption.
   
• Furthermore, the European Commission’s Health Program and national ministries have introduced initiatives to reduce respiratory morbidity, including funding for pulmonary rehabilitation, innovation in assistive technologies, and integration of respiratory care into primary health systems.
   
• The EU’s Capital Markets Union initiative and the Clearing Package Agreement aim to make the European healthcare and medical device ecosystem more competitive and resilient by improving supervisory coordination and accelerating market access. These developments, combined with growing demand for home-based care and digital health integration, position Europe as a steadily expanding market for airway clearance technologies.
   

Germany dominates the European airway clearance devices market, showcasing strong growth potential.
 

• Germany leads the European market due to its highly developed healthcare infrastructure, strong reimbursement systems, and proactive adoption of non-invasive respiratory therapies. The country’s statutory health insurance system covers a wide range of durable medical equipment, including airway clearance technologies, for chronic respiratory conditions such as cystic fibrosis.
   
• In recent years, the country has seen a rise in respiratory conditions such as COPD, asthma, and cystic fibrosis, attributed to aging demographics and environmental factors like air pollution. This has increased the need for effective airway management solutions.
   
• Additionally, Germany’s emphasis on innovation and its role in EU-wide regulatory harmonization under the Medical Device Regulation (MDR) make it a favorable environment for product launches and clinical adoption. These factors position Germany as a mature and innovation-friendly market with strong growth potential in the respiratory care segment.
   

Asia Pacific Airway Clearance Devices Market
 

The Asia Pacific market is anticipated to grow at the highest CAGR of 7.3% during the analysis timeframe.
 

• The growth is fueled by a combination of emerging respiratory disease burden, growth in healthcare access, and growing acceptance of non-invasive treatments. China, India, and Southeast Asia are seeing an increase in chronic respiratory illnesses such as COPD, asthma, and bronchiectasis due to urbanization, air pollution, and older population ages.
   
• Moreover, the area is also witnessing a trend towards non-invasive treatment solutions, such as oscillatory PEP devices and chest wall oscillation systems, which are becoming more and more favored compared to conventional hospital-based treatments.
   
• There are government programs like India's National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) and China's Healthy China 2030 plan that are aggressively investing in respiratory health infrastructure and assistive technologies. All these aspects together make Asia Pacific the fastest-growing market.
   

China airway clearance devices market is estimated to grow with a significant CAGR, in the Asia Pacific market.
 

• The country regularly faces increasing prevalence of conditions such as COPD, asthma, and bronchiectasis, driven by rapid urbanization, industrial pollution, and an aging population. In response, the Chinese government has launched major public health initiatives like Healthy China 2030, which prioritize respiratory health and promote access to advanced medical technologies.
   
• Additionally, awareness of non-invasive therapies is growing, supported by national guidelines and hospital-based education programs. Additionally, China’s investment in digital health and home-based care solutions is accelerating the adoption of airway clearance devices, especially in tier-2 and tier-3 cities where access to specialized care is limited.
   
• Furthermore, increased public awareness campaigns, urban lifestyle changes, and greater patient willingness to adopt minimally invasive therapies are supporting demand. With continuous improvements in hospital infrastructure, skilled physician training, and wider availability of advanced devices, China is expected to remain a key growth driver in the Asia Pacific market.
   

Latin American Airway Clearance Devices Market
 

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.
 

• The leadership of Brazil in the Latin American market for airway clearance devices is not only because of its massive population and respiratory disease burden but also because of its changing landscape of healthcare innovation. Brazil has experienced greater investment in public-private collaborations, especially through programs backed by the Ministry of Health and ANVISA (Brazil's health regulator), whose mandate is to bring speedier access to innovative medical technologies.
   
• There is a developing local manufacturing base for medical devices in Brazil, facilitated by incentives to local production and technology transfer contracts, which decrease costs and enhance availability of airway clearance systems.
   
• Also, Brazil is adding remote monitoring and telehealth to respiratory care, particularly in rural areas. This digital transformation facilitates increased utilization of airway clearance therapies in the home, augmented by mobile health platforms and community health agents.
   

Middle East and Africa Airway Clearance Devices Market
 

Saudi Arabia market to experience substantial growth in the Middle East and Africa market in 2024.
 

• Saudi Arabia is projected to experience substantial growth in the market within the Middle East and Africa region, driven by rising respiratory disease prevalence, expanding healthcare infrastructure, and strong government investment in medical technology.
   
• Public awareness is improving through national campaigns and partnerships with global health organizations, encouraging early diagnosis and the adoption of non-invasive treatment options such as oscillatory PEP devices and chest wall oscillation systems.
   
• Additionally, the Saudi Ministry of Health, under the Vision 2030 Health Sector Transformation Program, has prioritized respiratory care by expanding access to specialized clinics, investing in digital health platforms, and promoting home-based therapies.
   

Airway Clearance Devices Market Share

The market is highly competitive, with leading medical device companies focusing on product innovation, advanced technologies, and strategic collaborations to strengthen their market positions. Rising prevalence of chronic respiratory diseases, increasing patient awareness, and growing adoption of non-invasive therapies are driving companies to leverage research and development investments, digital health integration, and connected monitoring systems to enhance therapy effectiveness and improve patient outcomes. The global shift toward home-based and value-driven healthcare is also encouraging players to develop cost-effective, patient-centric solutions and expand their presence in emerging markets.
 

Key players include Baxter, Philips, Electromed, Tactile Medical, and Thayer Medical, collectively accounting for 72.1% of the global market. These companies maintain leadership through extensive product portfolios, strong global distribution networks, and continuous advancements in oscillatory PEP devices, high-frequency chest wall oscillation vests, and mechanical insufflation-exsufflation systems. Their dominance is reinforced by strategic partnerships with hospitals, homecare providers, and ambulatory centers to enhance accessibility and adoption.
 

Smaller and niche players are also gaining traction by focusing on portable, patient-friendly, and disease-specific devices. Competitive differentiation is increasingly defined by the ability to deliver technologically advanced, non-invasive, and cost-efficient airway clearance solutions tailored to diverse healthcare environments. As the market evolves, competition is expected to intensify, with both established leaders and emerging firms pursuing product innovation, digital health integration, and strategic alliances to capture greater market share.
 

Airway Clearance Devices Market Companies

Few of the prominent players operating in the airway clearance devices industry include:

• ABM Respiratory Care
• Baxter
• Dima Italia
• Dymedso
• Electromed
• ICU Medical
• Philips
• Mercury Medical
• Monaghan Medical Corporation
• Pari Medical
• Pneumo Care Health
• Sentec
• Tactile Medical
• Thayer Medical
• VORTRAN Medical Technology
• VYAIRE MEDICAL
   
•  Baxter

Baxter leads the airway clearance devices market with a share of 34.5% in 2024. Baxter’s USP lies in its advanced respiratory care portfolio, combining innovative airway clearance devices, homecare solutions, and digital health integration, ensuring reliable, patient-friendly therapies with strong global distribution and clinical support.
 

•  Philips

Philips differentiates itself through cutting-edge airway clearance technologies, including high-frequency chest wall oscillation systems and connected digital health solutions. Its devices emphasize patient comfort, portability, and remote monitoring capabilities, supported by extensive clinical validation and global reach, enabling enhanced respiratory care, higher adoption rates, and personalized treatment management across diverse healthcare settings.
 

Airway Clearance Devices Industry News:

• In May 2023, AffloVest received U.S. FDA 510(k) approval, enabling market availability. The company also secured clearance from Medicare, Medicaid, and private health insurance reimbursement, facilitating broader adoption of its respiratory devices and supporting growth in the U.S. healthcare market.
   
• In April 2023, Monaghan Medical and Premier Inc. signed an agreement to supply respiratory devices to clinicians. Monaghan will provide Premier members with Respiratory Therapy Medication Delivery devices and Oscillatory Positive Expiratory Pressure/Positive Airway Pressure devices, enhancing market presence and expanding their customer base.
   
• In January 2022, ICU Medical Inc. announced the acquisition of Smiths Medical from Smiths Group plc, a manufacturer of respiratory management and advanced medical devices. This acquisition expanded ICU Medical’s product portfolio and allowed access to a new customer base, strengthening its position in the respiratory devices market.
   
• In December 2021, Baxter acquired Hillrom, a medical technology company, to enhance geographic expansion and strengthen its business portfolio. The acquisition supports Baxter’s growth strategy by broadening its respiratory and medical device offerings and expanding its presence in key global markets.
   
• In September 2021, Tactile Medical acquired AffloVest’s respiratory therapy business from International Biophysics Corporation. This strategic move expanded Tactile Medical’s product portfolio and customer base, enhancing its position in the market and enabling access to advanced respiratory therapy solutions.
   

The airway clearance devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Device Type

• High frequency chest wall oscillation (HFCWO)
• Flutter mucus clearance device
• Intrapulmonary percussive ventilation (IPV)
• Mechanical cough assist devices
• Positive expiratory pressure (PEP)
• Other device types

Market, By Application

• Chronic obstructive pulmonary disease (COPD)
• Bronchiectasis
• Cystic fibrosis
• Neuromuscular
• Other applications

Market, By Age Group

• Adult
• Pediatric

Market, By End Use

• Homecare settings
• Hospital
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE